Not all evidence is built the same.
People here are treating this low tier evidence the same as a proper RCT.
Theres a reason that's not how it works in the scientific community.
If you ever had to critique and discuss peer reviewed articles you would know even well designed RCTs with low p values have issues that need serious consideration.
Im simply not swayed by a company that consistently failed its trials, but then goes back, trawls through sub groups until it finds some significance, and then pushes it as a success. It's not a success, it has created another hypothesis that needs to be confirmed. That's it
Pick Today's Price Range Low-High... Just for Fun, page-401
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.010(0.92%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.11 | $1.05 | $5.002M | 4.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5697 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
-0.010 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.11 | $1.06 | 1181223 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| MSB (ASX) Chart |